Sellas Life Sciences Stock Beta
| SLS Stock | USD 1.66 0.07 4.40% |
Fundamental analysis of Sellas Life allows traders to better anticipate movements in Sellas Life's stock price by examining its financial health and performance throughout various phases of its business cycle.
Sellas | Beta | Build AI portfolio with Sellas Stock |
Sellas Life Sciences Company Beta Analysis
Sellas Life's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Sellas Life Beta | 2.32 |
Most of Sellas Life's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sellas Life Sciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Sellas Beta Driver Correlations
Understanding the fundamental principles of building solid financial models for Sellas Life is extremely important. It helps to project a fair market value of Sellas Stock properly, considering its historical fundamentals such as Beta. Since Sellas Life's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Sellas Life's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Sellas Life's interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Sellas Life Sciences has a Beta of 2.319. This is 169.65% higher than that of the Biotechnology sector and 66.83% higher than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
Sellas Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sellas Life's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sellas Life could also be used in its relative valuation, which is a method of valuing Sellas Life by comparing valuation metrics of similar companies.Sellas Life is currently under evaluation in beta category among its peers.
Sellas Life Current Valuation Drivers
We derive many important indicators used in calculating different scores of Sellas Life from analyzing Sellas Life's financial statements. These drivers represent accounts that assess Sellas Life's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Sellas Life's important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 417.1M | 770.5M | 412.0M | 265.0M | 636.5M | 731.4M | |
| Enterprise Value | 382.8M | 749.9M | 395.8M | 263.4M | 623.5M | 712.9M |
Sellas Life Institutional Holders
Institutional Holdings refers to the ownership stake in Sellas Life that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Sellas Life's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Sellas Life's value.| Shares | Atom Investors Lp | 2025-03-31 | 64.2 K | Ubs Group Ag | 2025-03-31 | 62.2 K | Jane Street Group Llc | 2025-03-31 | 58.5 K | Virtu Financial Llc | 2025-03-31 | 53.9 K | Mariner Wealth Advisors Llc | 2025-03-31 | 51.2 K | Two Sigma Investments Llc | 2025-03-31 | 48.3 K | Renaissance Technologies Corp | 2025-03-31 | 34.9 K | Jain Global Llc | 2025-03-31 | 27.4 K | Gsa Capital Partners Llp | 2025-03-31 | 22.7 K | Anson Funds Management Lp | 2025-03-31 | 7.6 M | Vanguard Group Inc | 2025-03-31 | 2.8 M |
As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Sellas Life will likely underperform.
Sellas Fundamentals
| Return On Equity | -1.45 | ||||
| Return On Asset | -0.59 | ||||
| Current Valuation | 138.1 M | ||||
| Shares Outstanding | 99.78 M | ||||
| Shares Owned By Insiders | 0.33 % | ||||
| Shares Owned By Institutions | 14.84 % | ||||
| Number Of Shares Shorted | 27.74 M | ||||
| Price To Book | 5.97 X | ||||
| Price To Sales | 26.90 X | ||||
| Gross Profit | 900 K | ||||
| EBITDA | (30.88 M) | ||||
| Net Income | (30.88 M) | ||||
| Cash And Equivalents | 26.99 M | ||||
| Cash Per Share | 1.31 X | ||||
| Total Debt | 1 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 2.36 X | ||||
| Book Value Per Share | 0.30 X | ||||
| Cash Flow From Operations | (35.4 M) | ||||
| Short Ratio | 6.95 X | ||||
| Earnings Per Share | (0.36) X | ||||
| Target Price | 6.83 | ||||
| Number Of Employees | 15 | ||||
| Beta | 2.32 | ||||
| Market Capitalization | 158.65 M | ||||
| Total Asset | 19.43 M | ||||
| Retained Earnings | (248.12 M) | ||||
| Working Capital | 6.82 M | ||||
| Net Asset | 19.43 M |
About Sellas Life Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sellas Life Sciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sellas Life using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sellas Life Sciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Sellas Stock Analysis
When running Sellas Life's price analysis, check to measure Sellas Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sellas Life is operating at the current time. Most of Sellas Life's value examination focuses on studying past and present price action to predict the probability of Sellas Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sellas Life's price. Additionally, you may evaluate how the addition of Sellas Life to your portfolios can decrease your overall portfolio volatility.